Answers are grounded in this paper and cite their sources.
Background Pulmonary fibrosis (PF) is a progressive disease with limited therapeutic options, in which iron dyshomeostasis and ferroptosis have been increasingly implicated. This study investigated the anti-fibrotic effects of Feibi Recipe No. 2 (FBR2), a traditional Chinese medicine formula, and explored potential links among N-methyl-D-aspartate receptor (NMDAR) signaling, iron regulatory protein/iron-responsive element (IRP/IRE)-associated iron regulation, and ferroptosis-related changes. Methods The phytochemical profile of FBR2 was characterized by UHPLC-MS/MS. A bleomycin (BLM)-induced PF mouse model was established, with lung tissues collected on days 7, 14, and 21. Mice received FBR2 at 10.51, 21.02, or 42.04 g kg -1 ·day -1 (botanical-drug equivalents), with deferoxamine (DFO) as a comparator; the 21.02 g kg -1 ·day -1 dose was selected for subsequent time-course and mechanistic analyses. NMDAR signaling was modulated using the antagonist memantine (ME) and the agonist NMDA. Proteomic changes were profiled by data-independent acquisition (DIA), with selected proteins assessed by parallel reaction monitoring (PRM). Fibrotic phenotypes, iron-related changes, and ferroptosis-related alterations were evaluated by histological, immunological, biochemical, flow-cytometric, and IRP/IRE-related protein analyses. Results FBR2 attenuated BLM-induced PF in a stage-associated manner, preserving early-stage surfactant protein C (SPC)-positive alveolar epithelial cells, attenuating the early interleukin-6 (IL-6) inflammatory response, inhibiting mid-to-late-stage α-smooth muscle actin (α-SMA) expression, and decreasing late-stage collagen deposition. At day 21, FBR2-M significantly reduced Masson’s trichrome-positive area, modified Ashcroft score, and collagen I (Col I)-positive area (all vs. BLM, P < 0.0001). Proteomics identified 256 FBR2-reversed proteins enriched in iron metabolism- and ferroptosis-related pathways. Further analyses showed that FBR2 reduced pulmonary Fe 2+ accumulation and ameliorated iron-regulatory abnormalities, antioxidant impairment, lipid peroxidation, and mitochondrial dysfunction, collectively consistent with attenuation of ferroptosis-related injury. Pharmacological modulation of NMDAR revealed distinct response patterns: ME produced effects broadly similar to those of FBR2, whereas the FBR2 + NMDA group exhibited greater iron accumulation, more pronounced ferroptosis-related alterations, and more severe fibrotic changes than the FBR2 group, consistent with the potential involvement of NMDAR-related signaling in FBR2-mediated protection. Conclusion FBR2 attenuated PF progression, with its protective effects associated with NMDAR-related signaling, IRP/IRE-associated iron regulation, and attenuation of ferroptosis-related injury. Together, these findings support the involvement of these interconnected processes in FBR2-mediated protection against PF.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: